Tarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 12,500 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the sale, the director owned 106,786 shares in the company, valued at approximately $6,633,546.32. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $62.55 on Thursday. The stock has a market cap of $2.69 billion, a PE ratio of -54.87 and a beta of 0.49. The company’s fifty day moving average is $63.47 and its 200 day moving average is $69.54. Tarsus Pharmaceuticals, Inc. has a 52 week low of $38.51 and a 52 week high of $85.25. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. Research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after acquiring an additional 127,470 shares during the period. TimesSquare Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 24.3% in the fourth quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after acquiring an additional 64,941 shares during the period. Citigroup Inc. increased its position in shares of Tarsus Pharmaceuticals by 78.1% in the third quarter. Citigroup Inc. now owns 40,591 shares of the company’s stock valued at $2,412,000 after acquiring an additional 17,797 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Tarsus Pharmaceuticals by 19.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock valued at $8,995,000 after acquiring an additional 18,267 shares during the period. Finally, D.A. Davidson & CO. purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $1,493,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of analyst reports. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $90.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.